Prostate Cancer

CHICAGO — In this Healio video exclusive, Stephen J. Freedland, MD, discusses the racial differences regarding treatment escalation after androgen deprivation therapy in patients with prostate cancer.

CHICAGO — In this Healio video exclusive, Stephen J. Freedland, MD, discusses the underutilization of MRI-guided biopsies before prostate cancer diagnosis in different racial groups.

The FDA has approved niraparib and abiraterone acetate with prednisone for the treatment of deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer, or mCRPC, according to a press release.

SANTA FE, N.M. — In this video exclusive, Azeez Farooki, MD, discusses considerations when dealing with bone loss and elevated fracture risk resulting from treatments for breast and prostate cancer.

Men with very high-risk prostate cancer treated at high-volume radiation therapy treatment facilities survived significantly longer than those treated at low-volume centers, according to study results.

The FDA announced several regulatory actions the past few weeks.

Black men with metastatic castration-sensitive prostate cancer achieved OS and PFS comparable to white men when treated in a clinical trial setting, according to results of the randomized phase 3 SWOG 1216 trial.

Supervised resistance and aerobic exercise appeared to improve sexual function among men with prostate cancer, according to study results presented at ASCO Breakthrough.

An analysis of online conversations among health care professionals on social media in June revealed overwhelming support for FDA approvals of therapies for prostate cancer and lymphoma.

Black individuals are significantly more likely to trust the accuracy of online video content about prostate cancer presented by Black physicians or patients compared with white presenters, results of a randomized study showed.